Preclinical characterization of a Selective FGFR2/3 inhibitor, GSC000829

被引：0
|
作者：
Han, T. [1 ]
Fu, D. [1 ]
Cheng, T. [1 ]
Xia, Y. [1 ]
Hu, Z. [1 ]
Yang, F. [1 ]
机构：
[1] Changchun GeneSci Pharmaceut Co Ltd, Chem Drug Res & Dev, Shanghai, Peoples R China
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114647
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB112
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [21] FGFR2/3 in urothelial carcinoma
    Rose, Michael
    Gaisa, Nadine T.
    PATHOLOGIE, 2024, 45 (06): : 409 - 411
  • [22] Alofanib, a novel allosteric FGFR2 inhibitor, shows potent antitumor activity in ovarian cancer with FGFR2 expression
    Tjulandin, Sergei
    Byakhov, Mikhail
    Stepanova, Evgenia
    Khochenkov, Dmitry
    Harrison, Daniel
    Tsimafeyeu, Ilya
    CANCER RESEARCH, 2015, 75
  • [23] From Fragment to Lead: De Novo Design and Development toward a Selective FGFR2 Inhibitor
    Turner, Lewis D.
    Trinh, Chi H.
    Hubball, Ryan A.
    Orritt, Kyle M.
    Lin, Chi-Chuan
    Burns, Julie E.
    Knowles, Margaret A.
    Fishwick, Colin W. G.
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (02) : 1481 - 1504
  • [24] Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor
    Schram, A.
    Borad, M.
    Sahai, V.
    Kamath, S.
    Kim, R.
    Liao, C. Y. A.
    Oh, D. Y.
    Ponz-Sarvise, M.
    Yachnin, J.
    Shell, S. A.
    Cassier, P.
    Dotan, E.
    Florou, V.
    Moreno, V.
    Park, J. O.
    Tai, D.
    Schmidt-Kittler, O.
    Ferte, C.
    Goyal, L.
    Subbiah, V.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S116 - S116
  • [25] Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344
    Wickstroem, Katrine
    Hagemann, Urs B.
    Kristian, Alexander
    Ellingsen, Christine
    Sommer, Anette
    Ellinger-Ziegelbauer, Heidrun
    Wirnitzer, Uta
    Hagelin, Else-Marie
    Larsen, Aasmund
    Smeets, Roger
    Bjerke, Roger M.
    Karlsson, Jenny
    Ryan, Olav B.
    Wengner, Antje M.
    Linden, Lars
    Mumberg, Dominik
    Cuthbertson, Alan S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (02): : 410 - 422
  • [26] Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors
    Li, Gary
    Krook, Melanie
    Roychowdhury, Sameek
    Avogadri, Francesca
    Ye, Yining
    Moran, Susan
    CANCER RESEARCH, 2019, 79 (13)
  • [27] Characterization of FGFR1, FGFR2 and FGFR3 mutations in 45 Brazilian patients with craniosynostosis.
    Passos-Bueno, MR
    Sertié, AL
    Richieri-Costa, A
    Alonso, LG
    Zatz, M
    Alonson, N
    Brunoni, D
    Ribeiro, SFM
    Cavalheiro, S
    AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (04) : A342 - A342
  • [28] FGFR2 targeting with allosteric inhibitor RPT835
    Tsimafeyeu, I.
    Daeyaert, F.
    Yin, W.
    Ludes-Meyers, J.
    Byakhov, M.
    Tjulandin, S.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 155 - 155
  • [29] Discovery of LHQ490 as a highly selective fibroblast growth factor receptor 2 (FGFR2) inhibitor
    Li, Huiqiong
    Ke, Ran
    Zhou, Yang
    Chang, Shaohua
    Wang, Jie
    Su, Chen
    Wu, Pinglian
    Yang, Bowen
    Wang, Zhen
    Ding, Ke
    Ma, Dawei
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 272
  • [30] Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification
    Kim, Seung Tae
    Lee, In Kyoung
    Rom, Eran
    Sirkis, Roy
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    Kim, Kyoung-Mee
    Yayon, Avner
    Lee, Jeeyun
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2019, 11 (07): : 4508 - 4515
12345